Aclarion, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 28, 2024. Although the request references 2023 Q4, the filing reports annual results; it does not provide a clear standalone fourth-quarter income statement or cash-flow summary.
Business context
Aclarion is an early-stage healthcare technology company commercializing Nociscan, a cloud-based service that processes magnetic resonance spectroscopy data to help clinicians assess whether lumbar discs may be sources of pain. The company reports limited sales to date and is focused on payer coverage, clinical evidence, and broader commercial adoption. Its system is currently compatible with certain Siemens scanner models.
Financial performance and liquidity
| Metric | FY2023 | FY2022, restated | Change |
|---|---|---|---|
| Revenue | $75,404 | $60,444 | +$14,960 |
| Cost of revenue | $75,728 | $65,298 | +$10,430 |
| Gross profit (loss) | $(324) | $(4,854) | Improved $4,530 |
| Operating expenses | $4,875,657 | $5,556,714 | Down $681,057 |
| Operating loss | $(4,875,981) | $(5,561,568) | Improved $685,587 |
| Net loss | $(4,911,374) | $(7,068,593) | Improved $2,157,219 |
| Cash used in operating activities | $(3,646,947) | $(4,949,112) | Use decreased $1,302,165 |
Revenue increased about 25%, primarily from higher utilization in third-party clinical studies; volumes and pricing were generally consistent. Cost of revenue exceeded revenue, leaving a slightly negative gross margin. The net loss narrowed mainly because 2022 included substantial executive stock-option compensation and a $1.3 million beneficial-conversion interest charge. FY2023 also included a $646,319 noncash gain from changes in the fair value of warrant and derivative liabilities.
At December 31, 2023, cash and cash equivalents were $1,021,069, plus $10,000 of restricted cash. Current assets were $1.29 million versus current liabilities of $3.19 million. Total assets were $2.46 million, and stockholders’ equity was negative $728,000. The company reported $2.594 million principal amount of unsecured notes, with a net carrying amount of $1.126 million after discounts and financing costs. Stated note maturities included April, May, and September 2024.
Financing activities provided $3.315 million in 2023, including $2.25 million of note proceeds and $1.463 million from the equity line, partly offset by issuance costs. The company and auditor disclosed substantial doubt about the company’s ability to continue as a going concern. Management estimated cash would fund operations into Q3 2024, near a note repayment due in September, and said further funding would be needed.
Material changes and subsequent events
- FY2022 financial statements were restated to correct errors. The filing states the errors did not affect cash, revenue, or liquidity.
- In January 2024, the company completed a 1-for-16 reverse stock split, which the filing reflects retrospectively in share and per-share data.
- In January 2024, the company exchanged $1.520 million of note principal and accrued interest for common shares; after a March payment, the stated remaining principal and interest balance was $898,380.
- A February 2024 public offering generated approximately $3.0 million gross and $2.7 million net proceeds. The company said proceeds would support clinical studies, debt repayment, product development, sales and marketing, and general corporate purposes.
- Through March 15, 2024, the company reported $2.912 million of proceeds from White Lion equity-line share sales. The equity line permits up to $10 million in aggregate purchases, subject to conditions, and may dilute existing shareholders.
- In January 2024, Aclarion announced a strategic partnership agreement with ATEC Spine involving surgeon evaluations, clinical assessment, and potential co-marketing, subject to the contemplated steps and results.
Outlook, risks, and unusual items
- No specific revenue, earnings, or cash-flow guidance is provided. Management’s stated priorities include obtaining payer coverage for Category III CPT codes, expanding clinical evidence and registries, increasing physician and imaging-center adoption, and expanding scanner compatibility.
- The company’s Category III CPT codes are temporary; broad payer coverage and conversion to permanent Category I codes are not assured. The company says most revenue to date has come from patients paying out of pocket.
- Management and the auditor identify going-concern uncertainty. The runway estimate depends on assumptions, and the company expects to need additional capital. Equity financing may dilute shareholders; debt may add repayment obligations and restrictions.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end, citing limited segregation of duties, inadequate formal control documentation, limited resources, and insufficient accounting resources for complex transactions. The company engaged outside advisory firms to assist.
- European regulatory compliance is a material risk: the company expected its product to require Notified Body review under the EU Medical Device Regulation and disclosed that it had not yet engaged a Notified Body. It also described work to address post-market surveillance requirements.
- Clinical claims rely substantially on a company-sponsored, single-center study involving an author with a financial relationship with Aclarion. The filing cautions that the findings may not be replicated.
- The filing notes Nasdaq listing-compliance deficiencies during 2022–2023; it reports that the company regained bid-price compliance after the reverse split and equity compliance after the February 2024 offering, but remains subject to a one-year Nasdaq panel monitor for the equity requirement.
- Other key risks include dependence on Siemens-compatible scanners, limited commercial adoption, reimbursement uncertainty, privacy and cybersecurity obligations, intellectual-property and UCSF-license dependence, and potential dilution from warrants and equity-line shares.
Important facts for investors to verify
- Confirm the post-filing cash position, remaining note balances and exact repayment dates, and whether additional financing is required to extend the stated runway.
- Reconcile the reported 825,459 shares outstanding at December 31, 2023 with the 7,153,500 shares reported outstanding as of March 28, 2024, including offering shares, warrants, and reverse-split effects.
- Track actual payer coverage, utilization and reimbursement for the Category III codes, and progress toward Category I codes.
- Verify progress on EU MDR/Notified Body requirements and continued eligibility to market in the EU and UK.
- Review remediation of the disclosed internal-control material weaknesses and the implications of the 2022 financial-statement restatement.
- Assess whether subsequent clinical studies reproduce the reported outcomes and whether commercial use expands beyond clinical-study activity.